Arbutus Biopharma (NASDAQ:ABUS) Announces Quarterly Earnings Results, Beats Expectations By $0.90 EPS

Posted by Brian Himes on May 13th, 2026

Arbutus Biopharma (NASDAQ:ABUS – Get Free Report) announced its quarterly earnings data on Wednesday. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.03) by $0.90, FiscalAI reports. Arbutus Biopharma had a negative net margin of 237.88% and a negative return on equity of 42.39%. The company had revenue of $179.13 million during the quarter, compared to analysts’ expectations of $0.75 million.

Arbutus Biopharma Price Performance

Shares of ABUS stock traded down $0.02 during trading hours on Wednesday, hitting $4.30. The company had a trading volume of 1,002,664 shares, compared to its average volume of 2,061,108. The company’s fifty day moving average is $4.42 and its 200 day moving average is $4.43. Arbutus Biopharma has a fifty-two week low of $2.94 and a fifty-two week high of $5.10. The stock has a market capitalization of $845.86 million, a PE ratio of -25.26 and a beta of 0.62.

Hedge Funds Weigh In On Arbutus Biopharma

Several large investors have recently made changes to their positions in the stock. Invesco Ltd. lifted its holdings in shares of Arbutus Biopharma by 17.9% in the 4th quarter. Invesco Ltd. now owns 247,254 shares of the biopharmaceutical company’s stock worth $1,189,000 after acquiring an additional 37,616 shares during the last quarter. Mercer Global Advisors Inc. ADV lifted its holdings in shares of Arbutus Biopharma by 15.8% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 45,120 shares of the biopharmaceutical company’s stock worth $217,000 after acquiring an additional 6,161 shares during the last quarter. Virtus Investment Advisers LLC lifted its holdings in Arbutus Biopharma by 77.7% during the 4th quarter. Virtus Investment Advisers LLC now owns 56,483 shares of the biopharmaceutical company’s stock worth $272,000 after buying an additional 24,699 shares in the last quarter. Oxford Asset Management LLP purchased a new position in shares of Arbutus Biopharma in the 4th quarter valued at $104,000. Finally, Man Group plc grew its position in shares of Arbutus Biopharma by 52.2% in the 4th quarter. Man Group plc now owns 120,821 shares of the biopharmaceutical company’s stock valued at $581,000 after buying an additional 41,447 shares during the last quarter. 43.79% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arbutus Biopharma in a research note on Monday, April 20th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $5.00.

Check Out Our Latest Analysis on ABUS

About Arbutus Biopharma

(Get Free Report)

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company dedicated to discovering, developing and advancing a cure for chronic hepatitis B virus (HBV) infection. The company’s pipeline features both direct-acting antivirals and host-targeting therapies designed to reduce viral load and restore immune function. Lead programs include an RNA interference (RNAi) candidate aimed at silencing viral gene expression and next-generation capsid assembly modulators that seek to inhibit viral replication at its core.

In addition to its antiviral portfolio, Arbutus leverages proprietary lipid nanoparticle (LNP) delivery technology to optimize the distribution and cellular uptake of nucleic acid therapeutics.